First epigenetic reprogramming trial in the eye; cardiovascular use is speculative
Louis comments on the start of a clinical trial using Yamanaka-factor epigenetic reprogramming to restore youthful cell states in the eye. The eye is the testing site because it is isolated from the body by the blood-ocular barrier, limiting cancer risk. He says if it works and is safe, cardiovascular regeneration could follow, which is speculation.